Colistin methanesulfonate (CMS) is the only prodrug of colistin available for clinical use for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Owing to its slow and variable release, an alternative is urgently required to improve effectiveness. Herein we describe a PEGylated colistin prodrug whereby the PEG is attached via a cleavable linker (col-aaPEG) introducing an acetic acid terminated poly (ethylene glycol) methyl ether (aaPEG) onto the Thr residue of colistin. Due to the labile ester containing link, this prodrug is converted back into active colistin in vitro within 24 h. Compared to CMS, it showed a similar or better antimicrobial performance against two MDR isolates of Pseudomonas aeruginosa and Acinetobacter baumannii through in vitro disk diffusion, broth dilution and time-kill studies. In a mouse infection model, col-aaPEG displayed acceptable bacterial killing against P. aeruginosa ATCC 27853 and no nephrotoxicity was found after systemic administration, suggesting it to be a potential alternative for CMS.
Introduction
Bacterial infections, especially drug-resistant infections are a major global health issue [1] . The emergence of multidrug-resistant (MDR) strains of bacteria and the lack of new antibiotics is a worrying prospect for all of humanity [2] [3] [4] . A recent report suggests failing to control drug-resistant infections may cause in excess of 10 million deaths per year and cost up to US$ 100 trillion by 2050 [5] . MDR Gram-negative bacteria, are particularly difficult to treat due the nature of their robust outer membrane [6] . Colistin, a lipopeptide and member of the polymyxin family, is currently used as a last-line drug for the treatment of MDR Gram-negative bacterial infections [7] [8] [9] [10] .
Colistin is a cyclic lipopeptide with an intramolecular hydrophilic loop with a N-terminal fatty acyl group. The commercial colistin source contains two major components, colistin A and colistin B, of which the only difference is on the N-terminal fatty acyl group; a 6-methyloctanoic acid for colistin A and isooctanoic acid for colistin B (Fig. 1) [11] . The unique structure of colistin allows it to bind electrostatically with the bacterial outer membrane and then directly interact with the lipid A component of the lipopolysaccharide (LPS), the major constituent of the outer membrane of Gram-negative bacteria [12, 13] . The insertion of colistin disrupts the barrier function of the Gram-negative outer membrane that ultimately results in cell death.
The five primary amine groups on the 2,4-diaminobutyric acid (Dab) residues of colistin are essential to this process [13, 14] . The protonated amine groups can recognise and interact with the phosphorylated sugars on lipid A [13, 15, 16] . Unfortunately, while often used as a last defence for drug resistant infections this treatment is not allowed for systematic administration due to its associated nephrotoxicity [7, 17] .
One avenue to reduce the systemic toxicity of polymyxin is to formulate it into a prodrug form [18] . CMS is the only current FDA approved prodrug of colistin that can be used intravenously in the clinic [19] . After the modification on five primary amines to methanesulfonate groups, CMS is less toxic compared to the native colistin. However, the slow and variable colistin release rates from the prodrug form complicate its pharmacokinetics, resulting in variable treatment outcomes for patients [19] [20] [21] . A further concerning feature of the prodrug is the heterogeneity of the methanesulfonate modification which leads to supplier to supplier and batch to batch structural variation in the prodrug form [22] . Therefore, an alternative prodrug to CMS is highly desirable.
In polypeptide therapeutics, one favoured approach to improve the pharmacokinetic and pharmacodynamic properties of proteins/peptides is their conjugation to polymers [23] [24] [25] [26] [27] [28] . Amongst all polymers available, FDA approved biocompatible poly (ethylene glycol) (PEG) and its derivatives such as poly(ethylene glycol) methyl ether (mPEG) have been best studied and characterised [23, 27] . The attachment of PEG, known as PEGylation, onto those proteins/peptide drugs will help them bypass the enzymatic recognition, thus prevent them from antigenic/immunogenic recognition and proteolytic degradation [27, 29, 30] . PEGylation of protein/peptide drugs can also increase the hydrodynamic volume of the drugs, provide anti-fouling properties, prolonging their half-life, which can be important to decrease their toxicity to the kidney and improve patient compliance through longer dosing intervals [27] .
However, a significant (or sometimes complete) loss of the protein/ peptide activity has often been reported for many polymer-protein/ peptide conjugates following such modifications [25, 31, 32] . This has mainly been attributed to the blockage of the active site(s) or the altered structure of the protein/peptide caused by the polymer. Thus, prodrugs based on traceless and/or reversible conjugations have attracted significant attention [33] [34] [35] [36] . These types of prodrugs usually stay as an inactive or less active derivative under normal (storage) conditions, but can be converted back to the active drug at the targeted site/environment in vitro/in vivo. Several dynamic covalent bonds, especially disulphide bonds have been exploited to build up these releasable linkers [31, 35, 37, 38] . However, a non-releasable thiol containing spacer was required to be introduced onto the peptides/proteins that lack free cysteine residue(s). The remaining portion of the linker will sometimes modify the protein/peptide properties (such as the surface charge or solubility) and as such, has the potential to result in unwanted side effects, especially with small peptides. Recently, some other well-designed fully degradable or cleavable linkers, including 1,6-elimination [34] , thioester [35] , bicine [36] , and azidomethyl-methylmaleic anhydride (AzMMMan) [39] , were developed to target the more universal amine containing residues (i.e. lysine residues or a terminal amine) on the protein/peptide to achieve a traceless recovery of the native protein/ peptide.
In this work, we designed a PEGylated colistin prodrug with a sitespecific traceless releasable linker exhibiting low toxicity. This gave similar or better antibacterial activity to the commercial CMS prodrug. Although it might be considered that it would be more valuable to investigate reconversion rates under physiological conditions as here there would be esterases present previous work has looked at colistin and colistin methanesulfonate in both aqueous media and plasma it was found that the stability of and release of colistin from the CMS prodrug were comparable in both PBS buffer and plasma with no evidence of a role for esterases [22] . Instead of modifying the five Dab residues of colistin as in case of CMS, the two threonine (Thr) residues were targeted here as it can greatly reduce the site-diversity of the modification products. A relatively labile ester linkage was chosen to build up the colistin prodrug using an acetic acid terminated mPEG (aaPEG) considering the ester is a base and enzyme (i.e. lipase) hydrolysable bond that can be cleaved easily in the human body. In vitro degradation studies were performed to investigate colistin release rate. The effect upon the number of mPEG attachments and different linkages on colistin were also evaluated through the degradation studies. Moreover, the antibacterial activity of the PEGylate colistin prodrug was systematically studied through disk diffusion, broth dilution and time-kill experiments. In addition, a mouse thigh infection model was used to compare the activity performance and toxicity of the PEGylated colistin prodrug with colistin in vivo.
Materials and methods

Materials
Chemicals
All chemicals were purchased from Sigma-Aldrich and used directly unless otherwise stated. HPLC solvents are obtained from VWR international, LLC. The acetic acid functional mPEG (aaPEG, M n~2 kDa) was synthesised based on the previous report [40] . The succinic acid functional mPEG (saPEG, M n~2 kDa; commercial name: CH₃O-PEG-NHCO-C₂H₄-COOH; reference number: 122000-3) was purchased from Rapp Polymere GmbH.
Bacterial strains
Bacterial strains of P. aeruginosa ATCC 27853 and A. baumannii ATCC 19606 (American Type Culture Collection, Manassas, VA) were used in this study. The strains were stored at −80°C in a cryovial storage container (Simport Plastics, Quebec, Canada). Fresh isolates were subcultured on Nutrient agar (Media Preparation Unit, The University of Melbourne, Parkville, Australia) and incubated at 37°C for 24 h prior to each experiment. Cation-adjusted Mueller-Hinton broth (CAMHB; Oxoid, Hampshire, England) was used.
Methods
Disk diffusion assay
According to the EUCAST guidelines [41] , inoculum was standardised in saline to the density of a McFarland 0.50 ± 0.02 standard, corresponding to~10 8 CFU/mL of each isolate. Freshly prepared suspension was evenly inoculated onto plates and disks were applied within 15 min and incubated for 18 h at 37°C. Plates were examined for satisfactory streaked suspension and evenly distributed growth to achieve uniformly circular inhibition zones within the quality control limits.
Minimum inhibitory concentration (MIC) test
MICs were determined in accordance to the recommendations of the Clinical and Laboratory Standards Institute [42] . P. aeruginosa ATCC 27853 and A. baumannii ATCC 19606 were used for the tests. Experiments were performed with CAMHB in 96-well polystyrene microtiter plates. Wells were inoculated with 100 μL of bacterial suspension prepared in CAMHB (containing ∼10 6 CFU/mL) and 100 μL of CAMHB containing increasing concentrations of colistin, CMS and PEGylated colistin prodrugs (0-128 mg/L). The MIC measurements were carried out in duplicates with the MIC being defined as the lowest concentration at which visible growth was inhibited following 18-20 h of incubation at 37°C.
Time-kill test
The time-kill kinetics of the PEGylated colistin prodrugs at 0.5, 1, and 2 × MIC were examined against A. baumannii ATCC 19606. Briefly, each test sample was added into a 50 mL Eppendorf tube loaded with 20 mL of a logarithmic-phase broth culture of approximately 10 6 CFU/mL to yield concentrations of 0, 0.5, 1, and 2 × MIC (8 × MIC was also tested for col-aaPEG 2 ) of the isolate. The tubes were incubated in a shaking water bath at 37°C. The samples were taken at 0 min, 30 min and 1, 2, 4, 6 and 24 h. Subcultures for viable counts were performed on nutrient agar (Oxoid) using WASP2 Spiral Plater (Don Whitley Scientific) and incubated at 37°C for 24 h (48 h for plates with small colonies). Viable counts were determined by either manual counting or using ProtoCol3 Colony Counter (Don Whitley Scientific). The polymyxin-susceptible strain P. aeruginosa ATCC 27853 was cultured on nutrient agar plates. One colony was randomly selected and incubated overnight at 37°C. An aliquot of 0.2 mL of the overnight culture was dispersed in 20 mL CAMHB and incubated for the production of an early log-phase culture. Bacteria suspension was concentrated via centrifugation (3220 ×g for 10 min) and the resuspended in 0.9% sterile saline for inoculation onto mice. The bacterial concentration of 2 × 10 5 CFU/50 μL per mouse was estimated by determining the optical density (OD) at 600 nm and confirmed via plating onto agar. Swiss mice were rendered neutropenic via two intraperitoneally i.p. doses of cyclophosphamide, 4 days (150 mg/kg) and 1 day (100 mg/kg) prior to infection. Thigh infection was established by injecting i.v. bolus of 50 μL of the bacterial suspension (2 × 10 5 CFU/50 μL per mouse). Solutions for colistin, col-aaPEG and col-aaPEG 2 were prepared at 1 mg/mL in sterile saline solution (0.9%). At 2 h after inoculation, the mice were treated with 40 mg colistin base/kg of each compound or the same volume of saline, respectively, for the control group. At 0 h and 18 h after administration of either the compound or the control, the animals were sacrificed by an inhalation of isoflurane. The skin was disinfected with 70% ethanol and blood was collected via cardia puncture using a 1 mL syringe rinsed with 5000 IU/mL heparin, diluted serially in sterile 0.9% saline and plated on nutrient agar plates using WASP2 Spiral Plater (Don Whitley Scientific) and incubated at 37°C for 24 h (48 h for plates with small colonies). Viable counts were determined by either manual counting or using ProtoCol3 Colony Counter (Don Whitley Scientific). The bacterial load (log 10 CFU/mL) was calculated for each mouse. Experiments were conducted in duplicates and a mean and standard deviation (SD) was calculated.
In vivo efficacy study using a neutropenic mouse thigh infection model
Measurement of nephrotoxicity in mice
All animal experiments were approved by the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee. Mice were subcutaneously administered with either colistin or PEGylated colistin prodrugs at an accumulated dose of 40 mg colistin base/kg was achieved. At 20 h after the last dose, mice were euthanized by inhalation of an overdose of isoflurane. Immediately after sampling the blood by cardiac puncture (above) the right kidney of each mouse was collected and placed into 10% buffered formalin at pH 7.4 (Sigma, Australia) and stored in a 5 mL plastic tube. The formalin-fixed kidneys were subjected to histological examination at the Australian Phenomics Network, Histopathology and Organ Pathology (The University of Melbourne, Parkville, Australia). Samples were examined by a pathologist who was blind to the treatment groups. The nature and severity of the histological changes was graded as follows: (i) grade 1, mild acute tubular damage with tubular dilation, prominent nuclei and a few pale tubular casts; (ii) grade 2, severe acute tubular damage with necrosis; (iii) grade 3, acute necrosis/infarction.
The overall kidney histology score was calculated as a product of percentage score and grade score [43] . The SQR score (range: 0-5) was assigned as follows: (0): no significant change; (1): mild damage; (2): mild to moderate damage; (3): moderate damage; (4): moderate to severe damage; (5): severe damage.
Results and discussion
Synthesis of reversibly PEGylated colistin
For the site-specific modification of polymyxin we targeted the Thr residues. However, since the amines of the Dab residues in colistin are more chemically active than the hydroxyl groups of Thr residues, it was necessary to first protect each of the amine groups prior to the attachment of the polymer. A well-developed amine-protection approach using tert-butyloxycarbonyl (Boc) protecting groups was therefore applied (SFig. 1a). In order to ensure that all the five amines were fully protected, an excess of di-tert-butyl dicarbonate (Boc 2 O) was used with the addition of potassium carbonate (K 2 CO 3 ) during the modification. The reaction was carried out in a water/tetrahydrofuran (THF) mixed solvent system to prevent further reaction of Boc 2 O with the Thr residues. As commercial colistin has two major components (colistin A and colistin B), a double-peak pattern was observed during high performance liquid chromatography (HPLC) analysis of the native lipopeptide (SFig. 1b, black trace). An identical pattern, but at a higher retention time, was found following reaction with Boc 2 O, indicating the protecting groups were successfully introduced onto the amines, rendering the colistin much more hydrophobic (SFig. 1b, red trace). Further, a careful comparison by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-ToF MS) of the modified polymyxin to the double-peak pattern of native colistin measurements (SFig. 1c), revealed a 500 Da molecular weight increase confirmed that all five amines were modified whilst both hydroxyl groups of the Thr residues remained intact.
The Thr residues on Boc-protected colistin were then PEGylated using aaPEG via Steglich esterification (Fig. 2a) . As hydrolysis was to be used as the mechanism to release the native polymyxin from the prodrug form, aaPEG was chosen since the electron-withdrawing nature of the oxygen bonded to the α-carbon of the carboxyl group makes it a better leaving group thus rendering the ester bond formed less stable and more hydrolytically labile. Since there are two hydroxyl groups on the Boc 5 -colistin, two products with different molecular weight distributions, a mono-mPEG adduct (Boc 5 -col-aaPEG, M n Theory~3 .7 kDa, M n MALDI~3 .6 kDa, Fig. 2b ) and a bis-mPEG adduct (Boc 5 -col-aaPEG 2 , M n Theory~5 .7 kDa, M n MALDI~5 .5 kDa, Fig. 2c) , were obtained and isolated by HPLC from the reaction mixture at 20-22 min (SFig. 2b, black trace) and 18-20 min (SFig. 2b, green trace), respectively. A polymeric distribution with a typical PEG repeating unit of 44 Da and the double-peak pattern of colistin A and B can be clearly observed from the MALDI-ToF MS data of both adducts (Fig. 2d-e) , suggesting the successful attachment of aaPEG onto colistin.
The regeneration of amines on colistin was conducted under routine conditions for the cleavage of the Boc-protecting groups (Fig. 2a) . After the treatment with 33% TFA in DCM, the more hydrophilic deprotected products (col-aaPEG and col-aaPEG 2 ) were obtained. A successful deprotection was indicated by the clear shift to a shorter retention time during HPLC characterisation when c.f. the protected form (SFig. 2b). Moreover, only a slight decrease in the molecular weight was observed upon GPC characterisation (SFig. 2a), suggesting the ester bond between colistin and aaPEG remained unaffected during deprotection of both conjugates. Both col-aaPEG (M n Theory~3 .2 kDa, M n MALDI~3 .2 kDa, Fig. 2f ) and col-aaPEG 2 (M n Theory~5 .2 kDa, M n MALDI~5 .2 kDa, Fig. 2g ) retained the PEG polymeric distribution along with the colistin double-peak pattern through the MALDI-ToF MS data. About 500 Da molecular weight decrease was observed for the deprotected products, further confirming a full recovery of all the amines on the colistin conjugates.
The stability and the degradation of the mPEG-colistin conjugates
In order to study the cleavable nature of the ester bond, the degradation of both PEGylated conjugates was performed in vitro and monitored by HPLC (Fig. 3) . To mimic the physiological condition, the test was conducted at 37°C in phosphate buffered saline (PBS, pH = 7.4). For the col-aaPEG form, the signal of the conjugate decreased continuously with a co-committed appearance and increase in the typical colistin double-peaks up to 48 h (Fig. 3b) . Noticeably, we found that N75% colistin can be released from col-aaPEG within 6 h whilst it normally required N 24 h for CMS to achieve a similar extent of colistin release under similar conditions [22] . The two colistin peaks were then collected and analysed via MALDI-ToF MS confirming their identity as native colistin A and B (Fig. 3d-f ). This suggested that the released colistin was chemically unchanged and therefore potentially still active. As for col-aaPEG 2 , although the hydrolysis rate is almost twice as slow compared to colaaPEG in the first 6 h, a similar pattern was observed when following the reaction by HPLC with the colistin peaks appearing and increasing as a function of time, leading to full release of colistin within 48 h (Fig.  3c) . Interestingly, during degradation a broad peak appeared at 12-13.5 min, which coincided with the col-aaPEG conjugate. The intensity of this peak initially increased during the first 4 h and then decreased along with the full consumption of col-aaPEG 2 to furnish the native lipopeptides. This indicates that the release of colistin from col-aaPEG 2 undergoes a stepwise degradation process, proceeding via a col-aaPEG as an intermediate product (Fig. 3a) . Regardless, this also confirmed that the two aaPEGs which are attached onto the different Thr residues can both be hydrolysed during the degradation process to fully liberate native polymxins.
To investigate the effect of the traceless linker between mPEG and colistin, a second PEGylated colistin with a different ester bond was synthesised by the same protocol using a commercial available succinic acid terminated mPEG (saPEG) (Fig. 4a) . Lacking an electron-withdrawing oxygen bonded to the α-carbon, saPEG was expected to form a more stable conjugate. It was observed that colistin can still be released from both mono-and bis-saPEG modified products through the same hydrolysis protocol although the release rate is nearly twice slower than from the corresponding colistin aaPEG conjugates in the first 6 h (Fig. 4b-c) .
A similar degradation study was conducted at ambient temperature to evaluate the influence of temperature on the conjugate release (Fig. 4b-c) . As expected, the rate of hydrolysis for all the colistin conjugates was retarded compared to those at body temperature. In particular, the double-modified conjugates showed much slower release compared to the mono-adducts due to the stepwise nature of the hydrolysis process. All of the results implied that both ester linkers were temperature sensitive with regards to stability.
In vitro antimicrobial activity test of the colistin-aaPEG conjugates
The antibiotic activity of the PEGylated conjugates was subsequently tested against two different MDR Gram-negative bacteria strains (P. aeruginosa ATCC 27853 and A. baumannii ATCC 19606). A disk diffusion assay was first conducted using colistin and CMS as positive controls. The diameter of zone of inhibition (ZoI) of each conjugate is shown in Table 1 . Overall, aaPEG alone showed no antibiotic activity whereas both aaPEG modified colistin conjugates showed a clear ZoI. This indicated that the colistin conjugates exhibited antimicrobial activity and crucially that the activity did not occur as a result of the cleaved polymer but rather, from the released native colistin. Owing to the larger molecular weight and a slower colistin release rate, col-aaPEG 2 showed a smaller ZOI compared to col-aaPEG at the same loading amount (20 μg). Conversely, both saPEG modified colistin conjugates showed a smaller ZOI compared to the corresponding aaPEG modified colistin conjugates which is in agreement with the observed colistin Fig. 3. a) The proposed mechanism of the colistin release from the col-aaPEG 2 conjugate. The ability to release the col-aaPEG (b) and col-aaPEG 2 (c) conjugate at 37°C in PBS (1×) buffer was monitored by HPLC. The MALDI-ToF MS data of the commercial colistin (d) and the isolated colistin peaks (e and f) from the col-aaPEG prodrug solution after the incubation for 2 days. release profiles. Notably, col-saPEG 2 revealed no activity through the disk diffusion assay, indicating the attachment of PEG inhibited the activity of colistin and highlighting the need for a more labile, cleavable linker for the desired prodrug to maintain its activity over a time scale relevant to microbial proliferation.
To obtain a more accurate comparison of the relative activities of the prepared conjugates, minimum inhibitory concentration (MIC) assays were performed ( Table 2 ). The results revealed that the col-aaPEG conjugate behaved similarly to the native colistin in terms of the molar activity. This suggests that nearly full cleavage can be achieved from this colistin conjugate. Furthermore, the released colistin was chemically identical to native colistin, as confirmed during chemical characterisation (Fig. 3) , and crucially that activity of the released polymxin was retained. More interestingly, even though the molecular weight of the col-aaPEG are nearly twice the commercial prodrug CMS (M n CMS~1 743 g mol
), less material was required to inhibit the bacteria, indicating that the colistin release profile of the col-aaPEG prodrug is more efficient than of CMS in the selected bacteria growth media. In agreement with the colistin release profiles (Fig. 4b) and disk diffusion assay (Table 1) , the col-saPEG conjugate showed a lower activity (2-4 times) than the aaPEG conjugate, highlighting the need for faster colistin release to inhibit the growth of bacteria. Conversely, both double PEGylated prodrugs exhibited less activity against both bacteria strains on both mass and molar basis due to the molecular weight of the prodrugs as well as the slower degradation process. Especially colsaPEG 2 showed no activity in the selected concentration range, confirming the inhibition of the bacteria growth results from the release of colistin rather than from the prodrug itself.
In order to determine a better understanding of the killing kinetics of the prodrug conjugates, time-kill studies were subsequently conducted by incubating A. baumannii ATCC 19606 bacteria strain as a model with colistin, CMS and colistin-aaPEG conjugates. The time-kill curves for selected dosage regimen are shown in Fig. 5 . Three different doses (0.5 × MIC, 1 × MIC, and 2 × MIC, referring to mass based MICs of each compound) were initially tested. At the lower dose (0.5 × MIC), neither CMS nor aaPEG prodrugs exhibited inhibition with the killing curves essentially indistinguishable from those of the control, whereas colistin showed antibacterial killing in the first 6 h (Fig. 5a) . By increasing the dose to 1 × MIC and 2 × MIC of both CMS and col-aaPEG, antimicrobial activity was observed with col-aaPEG performing better at both doses than CMS (Fig. 5b-c) . Particularly, col-aaPEG could inhibit the growth of bacteria to below the detection limit within 30 min at 2 × MIC, whilst it takes 4 h for CMS to control the bacteria growth close to the detection limit. At all three dosage regimens, col-aaPEG 2 did not show any inhibition against the bacteria which is possibly due to the slower degradation rate compared to the bacteria growth rate.
However, it still showed an antibacterial killing at 30 min up to 4 h with regrowth occurring at 24 h when using a higher dose (8 × MIC) (Fig. 5d, purple trace) .
In vivo antimicrobial activity and toxicity evaluation of the colistinaaPEG conjugates
Due to the encouraging in vitro performance from the col-aaPEG prodrugs, the in vivo efficacy of these two labile ester based conjugates (col-aaPEG and col-aaPEG 2 ) was investigated in comparison to native colistin treatment against P. aeruginosa ATCC 27853 in a neutropenic mouse thigh infection model, the gold standard method was employed [49] . Colistin was employed as the comparator as the highly variable release and inter-batch heterogeneity of CMS yields large data fluctuations. After 18 h administration of colistin and the aaPEG prodrugs (40 mg colistin base/kg), a significant reduction in the bacterial burden was observed for both colistin (mean log 10 CFU/thigh 0.73 ± 1.46) and col-aaPEG (mean log 10 CFU/thigh 4.77 ± 0.89) compared to the 0 h (mean log 10 CFU/thigh 5.85 ± 0.06, N91.6% bacteria kill). However, col-aaPEG 2 failed to produce sufficient bacterial killing in vivo (mean log 10 CFU/thigh 8.75 ± 0.12). (Fig. 6a) Nephrotoxicity remains a dose-limiting issue with the broader application of polymyxin therapy as it impacts the ability of clinicians to increase the dose [44] [45] [46] [47] [48] [49] [50] . Therefore, in the present study, the in vivo apoptotic effect of col-aaPEG and col-aaPEG 2 was examined through the histological examination of the kidneys from mice subcutaneously administered either colistin or PEGylated colistin prodrugs at an accumulated dose of 40 mg colistin base/kg (Fig. 6b) . The kidneys of mice administered with the saline control had no observable histological damage (semi quantitative SQR score of 0, Fig. 6c ). In comparison, the histological examination of the kidneys from the mice treated with colistin, col-aaPEG 2 showed comparable mild histological damage with tubule damage, i.e. tubular dilation and degeneration (semi quantitative SQR score of 1, Fig. 6d, f) . Encouragingly, the kidneys of mice treated with col-aaPEG had no significant histological damage and were essentially comparable to the saline control (grade 0 histology kidney scoring; Fig. 6e ). These results demonstrate that colistin and col-aaPEG 2 (both grade 1 histology kidney scoring) appears to be more nephrotoxic than col-aaPEG (Fig. 6) . The observation that the doubly PEGylated prodrug generates more nephrotoxicity than the mono-PEGylated prodrug is interesting. As the histology assay is well validated it is obviously not as simple as correlating nephrotoxicity with rates of colistin release, the observed differences more likely reflects the complex and different renal handling mechanism at play for the mono-PEGylated vs the doubly PEGylated prodrug [13] . 
Conclusions
In this work, fully characterised mono-and bis-mPEG modified colistin conjugates with two different ester linkages on the Thr residue(s) of colistin were synthesised via Boc-protection/deprotection and Steglich esterification. All the prodrug candidates were tested through the in vitro degradation studies and revealed native colistin can be released smoothly from all the colistin conjugates and that the colistin release rate from the PEGylated conjugates can be altered by the number of mPEG attachment and the lability of the linker. It is noted that a full PK study is well beyond the scope of the study and this would require the development of a validated assay that takes into account the stability of the prodrug during storage periods and during assay. Studies also showed the degradation process is temperature sensitive and the prodrugs are relatively stable at ambient temperature. Among them, the col-aaPEG showed the fastest colistin release rate, achieving near full colistin release within 24 h, which makes it a viable prodrug candidate. All in vitro antimicrobial activity tests suggested col-aaPEG performs with a similar or better activity relative to the commercial prodrug CMS or colistin on both molar and mass basis. In comparison to colistin, col-aaPEG showed acceptable bacterial killing in an in vivo mouse model against P. aeruginosa ATCC 27853 and displayed no nephrotoxicity through the histological examination of the kidneys. Although further evaluation is needed to determine whether this activity profile of col-aaPEG in vivo extends to other Gram-negative species, we believe that due to the enhanced specificity confirmed by targeting Thr residues without loss of antibacterial civility, col-aaPEG has the potential candidate to become a potent alternative prodrug to CMS.
